Clinical trial
Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors
NCT00091806 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00091806 |
|---|---|
| Title | Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors |
| Official title | An Open-Label, Clinical Trial Evaluating the Safety and Pharmacokinetics of Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors, Oncology, Solid Tumors |
| Intervention type | Drug |
| Interventions | panitumumab (ABX-EGF), Panitumumab |
| Enrollment | 86 |
| Start date | Aug 1, 2004 |
| Primary completion | Apr 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Sep 21, 2004 |
| Last update posted | Jul 10, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: